
Open Book Extracts (OBX) entered into a partnership with Biopharmaceutical Research Company (BRC). Under the terms of the collaboration, OBX will leverage BRC's research platforms, in order to develop research-backed formulations and products including Delta-9 THC.
From preclinical and first-in-human dosage forms to optimization of formulations for late-stage development and market following clinical evaluation, OBX will work closely with BRC to develop the most appropriate formulation based on the physicochemical and biopharmaceutics properties of the cannabinoids of interest, the intended route of administration and the phase of development. The partnership with BRC also supports the study of Delta-9 THC products and formulations, allowing OBX to identify the phase appropriate, optimal products for formulations including Delta-9 THC.